{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:25:49Z","timestamp":1758893149111},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sandoz Biopharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2020-0360_abs_001_w2aab3b7c12b1b6b1aab1c15b1Aa\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Omnitrope<jats:sup>\u00ae<\/jats:sup> (somatropin, Sandoz Inc.) is one of several recombinant human growth hormones (rhGH) approved in the United States (US) for use in pediatric indications, including growth hormone deficiency (GHD) and idiopathic short stature (ISS). We report data on the effectiveness and safety of Omnitrope<jats:sup>\u00ae<\/jats:sup> in the US cohort of the PATRO Children (international, longitudinal, non-interventional) study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0360_abs_002_w2aab3b7c12b1b6b1aab1c15b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All visits and assessments are carried out according to routine clinical practice, and doses of Omnitrope<jats:sup>\u00ae<\/jats:sup> are given according to country-specific prescribing information.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0360_abs_003_w2aab3b7c12b1b6b1aab1c15b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>By September 2018, 294 US patients were recruited; the two largest groups were GHD (n=193) and ISS (n=62). Across all indications, HSDS improvement (\u0394HSDS) from baseline at three years was +1.0 (rhGH-na\u00efve, +1.2; pre-treated, +0.7). In pre-pubertal patients, \u0394HSDS from baseline at three years was +0.94 (rhGH-na\u00efve, +1.3; pre-treated, +0.7). Following three years of treatment, \u0394HSDS from baseline was +1.3 in rhGH-na\u00efve GHD patients and +1.1 in rhGH-na\u00efve ISS patients. In pre-pubertal rhGH-na\u00efve patients, \u0394HSDS from baseline was +1.3 and +1.2 in GHD and ISS patients, respectively. Overall, 194 patients (66.0%) experienced adverse events (AEs; n=886 events); most were of mild-moderate intensity. Five patients (1.7%) had AEs that were suspected to be treatment-related (n=5 events). All reported neoplasms were benign, non-serious, and considered unrelated to rhGH therapy. No AEs of diabetes mellitus or hyperglycemia were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0360_abs_004_w2aab3b7c12b1b6b1aab1c15b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Omnitrope<jats:sup>\u00ae<\/jats:sup> appears to be well tolerated and effective in the majority of patients, without evidence of an increased risk of developing unexpected AEs, diabetes mellitus, or new malignancies during treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2020-0360","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T18:27:49Z","timestamp":1614623269000},"page":"431-440","source":"Crossref","is-referenced-by-count":5,"title":["PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope<sup>\u00ae<\/sup> (somatropin) treatment in children: update on the United States cohort"],"prefix":"10.1515","volume":"34","author":[{"given":"Philippe","family":"Backeljauw","sequence":"first","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine , Cincinnati , OH , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley S.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Division of Pediatric Endocrinology, University of Minnesota , Minneapolis , MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Levy","sequence":"additional","affiliation":[{"name":"Rush University Medical Center , Chicago , IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"McCormick","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, University of Alabama at Birmingham , Birmingham , AL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hichem","family":"Zouater","sequence":"additional","affiliation":[{"name":"Sandoz GmbH , Holzkirchen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zabransky","sequence":"additional","affiliation":[{"name":"Sandoz GmbH , Holzkirchen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Campbell","sequence":"additional","affiliation":[{"name":"Sandoz Inc. , Princeton , NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"2023040101452975696_j_jpem-2020-0360_ref_001_w2aab3b7c12b1b6b1ab2b2b1Aa","unstructured":"Omnitrope\u00ae. Highlights of prescribing information. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5&type=display [Accessed 17 Mar 2020]."},{"key":"2023040101452975696_j_jpem-2020-0360_ref_002_w2aab3b7c12b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Grimberg, A, Allen, DB. Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence. Curr Opin Pediatr 2017;29:466\u201371.","DOI":"10.1097\/MOP.0000000000000505"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_003_w2aab3b7c12b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Richmond, E, Rogol, AD. Current indications for growth hormone therapy for children and adolescents. Endocr Dev 2010;18:92\u2013108.","DOI":"10.1159\/000316130"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_004_w2aab3b7c12b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Bell, J, Parker, KL, Swinford, RD, Hoffman, AR, Maneatis, T, Lippe, B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010;95:167\u201377.","DOI":"10.1210\/jc.2009-0178"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_005_w2aab3b7c12b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Pf\u00e4ffle, R, Schwab, KO, Marginean, O, Walczak, M, Szalecki, M, Schuck, E, et al.. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope\u00ae in children requiring growth hormone treatment. Ther Adv Endocrinol Metab 2013;4:3\u201311.","DOI":"10.1177\/2042018813479644"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_006_w2aab3b7c12b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Tanner, JM, Davies, PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985;107:317\u201329.","DOI":"10.1016\/S0022-3476(85)80501-1"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_007_w2aab3b7c12b1b6b1ab2b2b7Aa","unstructured":"Centers for Disease Control and Prevention. CDC growth charts. Available from: https:\/\/www.cdc.gov\/growthcharts\/cdc_charts.htm [Accessed 17 Mar 2020]."},{"key":"2023040101452975696_j_jpem-2020-0360_ref_008_w2aab3b7c12b1b6b1ab2b2b8Aa","unstructured":"Kanumakala, S, Pf\u00e4ffle, R, H\u00f6ybye, C, Kristr\u00f6m, B, Battelino, T, Zabransky, M, et al.. Latest results from PATRO Children\u00ae, a multi-centre, non-interventional study of the long-term safety and efficacy of Omnitrope\u00ae in children requiring growth hormone treatment. Horm Res Paediatr 2019;91:1\u2013682."},{"key":"2023040101452975696_j_jpem-2020-0360_ref_009_w2aab3b7c12b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Borr\u00e1s P\u00e9rez, MV, Kristr\u00f6m, B, Romer, T, Walczak, M, H\u00f6bel, N, Zabransky, M. Ten years of clinical experience with biosimilar human growth hormone: a review of safety data. Drug Des Dev Ther 2017;11:1497.","DOI":"10.2147\/DDDT.S130909"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_010_w2aab3b7c12b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Bonfig, W, Lindberg, A, Carlsson, M, Cutfield, W, Dunger, D, Camacho-H\u00fcbner, C, et al.. Efficacy of growth hormone treatment in children with type 1 diabetes mellitus and growth hormone deficiency-an analysis of KIGS data. J Pediatr 2018;198:260\u20134.","DOI":"10.1016\/j.jpeds.2018.02.035"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_011_w2aab3b7c12b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Cutfield, WS, Lindberg, A, Rapaport, R, Wajnrajch, MP, Saenger, P. Safety of growth hormone treatment in children born small for gestational age: the US trial and KIGS analysis. Horm Res 2006;65:153\u20139.","DOI":"10.1159\/000091719"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_012_w2aab3b7c12b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Polak, M, Blair, J, Kotnik, E, Pournara, E, Pedersen, BT, Rohrer, TR. Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet\u00ae International Outcome Study. Eur J Endocrinol 2017;177:421\u20139.","DOI":"10.1530\/EJE-16-1024"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_013_w2aab3b7c12b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Reiter, EO, Price, DA, Wilton, P, Albertsson-Wikland, K, Ranke, MB. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006;91:2047\u201354.","DOI":"10.1210\/jc.2005-2284"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_014_w2aab3b7c12b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"S\u00e4vendahl, L, Pournara, E, Pedersen, BT, Blankenstein, O. Is safety of childhood growth hormone therapy related to dose? Data from a large observational study. Eur J Endocrinol 2016;174:681\u201391.","DOI":"10.1530\/EJE-15-1017"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_015_w2aab3b7c12b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Carel, JC, Ecosse, E, Landier, F, Meguellati-Hakkas, D, Kaguelidou, F, Rey, G, et al.. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012;97:416\u201325.","DOI":"10.1210\/jc.2011-1995"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_016_w2aab3b7c12b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Poidvin, A, Touz\u00e9, E, Ecosse, E, Landier, F, B\u00e9jot, Y, Giroud, M, et al.. Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology 2014;83:780\u20136.","DOI":"10.1212\/WNL.0000000000000737"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_017_w2aab3b7c12b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Albertsson-Wikland, KA, M\u00e5rtensson, A, S\u00e4vendahl, L, Niklasson, P, Bang, J, Dahlgren, J. Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab 2016;101:2149\u201359.","DOI":"10.1210\/jc.2015-3951"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_018_w2aab3b7c12b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Berglund, A, Gravholt, CH, Olsen, MS, Christiansen, JS, Stoccholm, K. Growth hormone replacement does not increase mortality in patients with childhood-onset growth hormone deficiency. Clin Endocrinol 2015;83:677\u201383.","DOI":"10.1111\/cen.12848"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_019_w2aab3b7c12b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"S\u00e4vendahl, L, Maes, M, Albertsson-Wikland, K, Borgstr\u00f6m, B, Carel, JC, Henrard, S, et al.. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012;97:E213\u20137.","DOI":"10.1210\/jc.2011-2882"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_020_w2aab3b7c12b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Stochholm, K, Weiss, W. Long-term safety of growth hormone-A combined registry analysis. Clin Endocrinol 2018;88:515\u201328.","DOI":"10.1111\/cen.13502"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_021_w2aab3b7c12b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Swerdlow, AJ, Cooke, R, Beckers, D, Borgstr\u00f6m, B, Butler, G, Carel, JC, et al.. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study. J Clin Endocrinol Metab 2017;102:1661\u201372.","DOI":"10.1210\/jc.2016-2046"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_022_w2aab3b7c12b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Allen, DB, Backeljauw, P, Bidlingmaier, M, Biller, BM, Boguszewski, M, Burman, P, et al.. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol 2016;174:1\u20139.","DOI":"10.1530\/EJE-15-0873"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_023_w2aab3b7c12b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"S\u00e4vendahl, L, Cooke, R, Tidblad, A, Beckers, D, Butler, G, Cianfarani, S, et al.. Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study. Lancet Diabetes Endocrinol 2020;8:683\u201392.","DOI":"10.1016\/S2213-8587(20)30163-7"},{"key":"2023040101452975696_j_jpem-2020-0360_ref_024_w2aab3b7c12b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Grimberg, A, DiVall, SA, Polychronakos, C, Allen, DB, Cohen, LE, Quintos, JB, et al.. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 2016;86:361\u201397.","DOI":"10.1159\/000452150"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0360\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T21:47:36Z","timestamp":1680385656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0360\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,5]]},"published-print":{"date-parts":[[2021,4,27]]}},"alternative-id":["10.1515\/jpem-2020-0360"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2020-0360","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,26]]}}}